Opioid crisis: Criminal justice referrals miss treatment opportunities, study suggests

December 4, 2017, Johns Hopkins University Bloomberg School of Public Health

A new study by researchers at the Johns Hopkins Bloomberg School of Public Health found that under 5 percent of those referred for opioid treatment from the criminal justice system were directed to medication-assisted programs to treat their disorder. Medication treatment, usually consisting of methadone or buprenorphine, both of which are opioids, helps control symptoms of withdrawal and cravings that can cause relapse. It is considered the most effective way to manage opioid misuse and reduce opioid-related harms such as overdose.

In contrast, the researchers found that 40 percent of clients referred for by other sources, such as health-care providers, employers, or self-referral, attended medication-assisted programs. The referral gap suggests a missed opportunity to link one of the most at-risk groups of people into effective treatment at a time when the nation faces a deepening crisis.

The study appears in the December issue of Health Affairs.

"This new research demonstrates that a large majority of persons referred for from the system are not receiving optimal care for their disorder," says Noa Krawczyk, a doctoral student in the Bloomberg School's Department of Mental Health and the study's lead author. "This underutilization of medications is due to many factors, including the cultural stigma that these medications are 'replacing one drug for another' and that recovery can only be attained through abstinence. This thinking runs contrary to the scientific evidence." 

Justice-involved individuals are especially vulnerable. While there is no current data on opioid addiction among the incarcerated, an estimated two-thirds of people in U.S. correctional settings have a diagnosable substance-use disorder, the researchers note. An earlier study, from 2004, suggested that between nine and 13 percent of incarcerated individuals were using opioids regularly before their incarceration. Research suggests that incarcerated individuals have a greater than a hundred-fold higher risk of fatal overdose in the two weeks post-release than members of the general population.

For the study, researchers analyzed 72,084 first-time treatment admissions using the 2014 Treatment Episodes Data Set compiled and managed by the Substance Abuse and Mental Health Services Administration. The data included treatment admissions in 41 states and the District of Columbia and Puerto Rico. The sample included people age 18 and older who entered specialty treatment programs primarily for problems related to the use of opioids, including heroin, nonprescription methadone or other opiates or synthetics, such as prescription pain killers.

Of the 72,084 clients receiving treatment for opioid use in the sample, 24.3 percent - or 17,536 clients - were referred to treatment through the criminal system, i.e., police officials, judges, prosecutors, probation officers, and other persons affiliated with a federal, state, or county judicial system. Of these, only 805 clients, or 4.6 percent, were referred for .

To determine how different criminal justice bodies were referring individuals to medication-assisted treatment, the researchers conducted a second analysis of 13,459 people referred to opioid treatment, both medication-assisted and others, from the criminal justice system. They found that 38.7 percent were referred to some form of opioid treatment by probation or parole programs; 30.1 percent by state, federal, or other courts; 10.9 percent by diversionary programs; 2.6 percent by prisons; 2.1 percent through a DUI or DWI program; and 15.5 percent by other legal system referral sources.

The study found low rates of medication treatment regardless of specific referral source - clients referred from a DUI or DWI program were the most likely to be referred to medication treatment (9.9 percent), while clients referred from a diversionary program or a court were least likely to be referred to medication treatment (1.9 and 3.4 percent, respectively).

These findings suggest that while criminal justice referral to medication treatment is low overall, certain criminal justice bodies - such as courts and diversionary programs - may be high-priority targets for policy interventions to assure referred clients are receiving the highest quality of care. This is especially critical as specialty courts and diversionary programs are often designed to provide a mechanism through which people can be diverted to needed treatment as an alternative to incarceration. Promoting evidence-based care as part of this alternative is fundamental to assuring these programs achieve successful outcomes and reduce recidivism.

The most common type of medication-based treatment for opioid disorder, which is known as "opioid agonist therapy" takes two forms. Methadone treatment is administered through regulated outpatient opioid treatment programs while buprenorphine can also be prescribed by physicians who obtain a waiver from the Drug Enforcement Agency.

"If we want to address overdose risk among the most vulnerable people while also cutting down the constant cycle of people in and out jail, we need to get more effective treatment to people in the criminal justice system," says Brendan Saloner, PhD, assistant professor in the Bloomberg School's Department of Health Policy and Management and a senior author. "The justice system has an opportunity to be a vital partner to stem the tide of the opioid crisis."

In addition to cultural stigmas, there are regulatory hurdles to using medication treatment in settings where justice-involved individuals receive care, such as the need to obtain licensure from the Drug Enforcement Agency or fears about diversion, the authors note. 

"One solution is for policymakers to require criminal justice entities to support medications both within criminal justice settings, such as jails and prisons, and to encourage their use when justice-involved persons are referred for opioid use disorder treatment," says Krawczyk. "Efforts can be made to reduce stigma and educate criminal justice staff about the benefits of these medications in improving health and criminal justice outcomes.

"One in Twenty Justice-Referred Adults in Specialty Treatment for Opioid Use Receive Methadone or Buprenorphine" was written by Noa Krawczyk, Brendan Saloner, Kenneth Feder and Caroline Picher.

Explore further: Immediate access to opioid agonists found cost-effective

Related Stories

Immediate access to opioid agonists found cost-effective

November 22, 2017
(HealthDay)—Immediate access to opioid agonist treatment (OAT) for patients presenting with opioid use disorder may provide greater health benefits at less cost than observed standard of care, according to a study published ...

Program for offenders with mental health or addiction issues produces positive results

November 30, 2017
A review of a state program launched two years ago to improve recovery and reduce recidivism among felony offenders who have mental health or addiction issues shows the program is producing positive results.

Medicaid coverage for methadone improves treatment for opioid use disorder in pregnancy

November 14, 2017
Pregnant women with opioid use disorder (OUD) are more likely to receive evidence-based treatment with an "opioid agonist"—usually methadone—in states where those medications are covered by Medicaid, reports a study in ...

Medicaid patients continue high prescription opioid use after overdose

August 22, 2017
Despite receiving medical attention for an overdose, patients in Pennsylvania Medicaid continued to have persistently high prescription opioid use, with only slight increases in use of medication-assisted treatment, according ...

Starting opioid addiction treatment in the ED is cost-effective

August 16, 2017
The most cost-effective treatment for people with untreated opioid addiction who visit the emergency department (ED) is buprenorphine, a medication to reduce drug cravings and withdrawal, say Yale researchers. Their study ...

Largest study of opioid deaths reveals who is at most risk

November 28, 2017
Just over 60 percent of individuals who died from an opioid overdose had been diagnosed with a chronic pain condition, and many had been diagnosed with a psychiatric disorder, a study of more than 13,000 overdose deaths has ...

Recommended for you

Drug overdose epidemic has been growing exponentially for decades

September 20, 2018
Death rates from drug overdoses in the U.S. have been on an exponential growth curve that began at least 15 years before the mid-1990s surge in opioid prescribing, suggesting that overdose death rates may continue along this ...

Anti-cancer drugs may hold key to overcoming antimalarial drug resistance

September 20, 2018
Scientists have found a way to boost the efficacy of the world's most powerful antimalarial drug with the help of chemotherapy medicines, according to new research published in the journal Nature Communications.

Probiotic use may reduce antibiotic prescriptions, researchers say

September 14, 2018
Use of probiotics is linked to reduced need for antibiotic treatment in infants and children, according to a review of studies that probed the benefits of probiotics, say researchers in the U.S., England and the Netherlands.

Recalled blood pressure drugs not linked to increased short term cancer risk

September 12, 2018
Products containing the withdrawn blood pressure drug valsartan are not associated with a markedly increased short term risk of cancer, finds an expedited analysis published by The BMJ today.

Sugar pills relieve pain for chronic pain patients

September 12, 2018
Someday doctors may prescribe sugar pills for certain chronic pain patients based on their brain anatomy and psychology. And the pills will reduce their pain as effectively as any powerful drug on the market, according to ...

A new approach for finding Alzheimer's treatments

September 11, 2018
Considering what little progress has been made finding drugs to treat Alzheimer's disease, Maikel Rheinstädter decided to come at the problem from a totally different angle—perhaps the solution lay not with the peptide ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.